Cns Pharmaceuticals, Inc.
CNSPCIK 0001729427 · Every Form 4 filed by insiders at this issuer. See financials →
Annual report (10-K)
Latest 10-K/A filed Apr 30, 2026. Sentiment + YoY language diff vs prior year. Read sections →
Signal:NeutralFull-doc fallback
Full filing:tone 0.0019
Sentiment via Loughran-McDonald lexicon · YoY diff via Jaccard similarity + paragraph set difference.
Recent 8-K announcements
Per-item disclosure feed. Item 2.02 is the earnings release.
Top insiders
Most active reporters at Cns Pharmaceuticals, Inc.
| Name | Roles | Filings |
|---|---|---|
| Evans Carl Anthony | Director | 5 |
| Keyes Jeffry R. | Director | 5 |
| Mahery Amy | Director | 3 |
| Andraczke Andrzej | Director | 2 |
| Priebe Waldemar | 10% Owner | 2 |
Top performers
Insiders ranked by realized 90-day signed return on their open-market trades at Cns Pharmaceuticals, Inc.. Minimum 3 scored trades. Returns are signed - a sale followed by a rally counts against the insider.
| # | Insider | Trades | Win rate | Avg | Median | Best | Worst |
|---|---|---|---|---|---|---|---|
| 1 | Gumulka Jerzy | 3 | 67% | +76.4% | +18.6% | +224.4% | -13.8% |
| 2 | Climaco John M | 3 | 33% | +72.9% | -8.2% | +240.7% | -13.8% |
| 3 | Downs Christopher | 3 | 33% | +1.8% | -13.8% | +41.4% | -22.2% |
| 4 | Priebe Waldemar | 17 | 24% | -61.9% | -84.8% | +51.6% | -116.2% |
All filings
58 Form 4 / 4-A filings, newest first
| Filed | Top transaction | Shares | Price | Value | ||
|---|---|---|---|---|---|---|